- Home
- GUT vs TNGX Comparison
GUT vs TNGX Comparison
Compare GUT & TNGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GUT
- TNGX
- Stock Information
- Founded
- GUT 1999
- TNGX 2014
- Country
- GUT United States
- TNGX United States
- Employees
- GUT N/A
- TNGX 140
- Industry
- GUT Trusts Except Educational Religious and Charitable
- TNGX Biotechnology: Pharmaceutical Preparations
- Sector
- GUT Finance
- TNGX Health Care
- Exchange
- GUT Nasdaq
- TNGX Nasdaq
- Market Cap
- GUT 395.9M
- TNGX 317.4M
- IPO Year
- GUT N/A
- TNGX N/A
- Fundamental
- Price
- GUT $5.50
- TNGX $3.08
- Analyst Decision
- GUT
- TNGX Strong Buy
- Analyst Count
- GUT 0
- TNGX 8
- Target Price
- GUT N/A
- TNGX $13.14
- AVG Volume (30 Days)
- GUT 176.3K
- TNGX 1.2M
- Earning Date
- GUT 01-01-0001
- TNGX 11-06-2024
- Dividend Yield
- GUT 10.93%
- TNGX N/A
- EPS Growth
- GUT N/A
- TNGX N/A
- EPS
- GUT N/A
- TNGX N/A
- Revenue
- GUT N/A
- TNGX $43,383,000.00
- Revenue This Year
- GUT N/A
- TNGX $27.73
- Revenue Next Year
- GUT N/A
- TNGX N/A
- P/E Ratio
- GUT N/A
- TNGX N/A
- Revenue Growth
- GUT N/A
- TNGX 15.67
- 52 Week Low
- GUT $4.60
- TNGX $2.59
- 52 Week High
- GUT $7.38
- TNGX $13.01
- Technical
- Relative Strength Index (RSI)
- GUT 60.77
- TNGX 48.20
- Support Level
- GUT $5.35
- TNGX $2.60
- Resistance Level
- GUT $5.45
- TNGX $3.65
- Average True Range (ATR)
- GUT 0.10
- TNGX 0.26
- MACD
- GUT 0.03
- TNGX 0.03
- Stochastic Oscillator
- GUT 100.00
- TNGX 46.48
About GUT Gabelli Utility Trust (The)
Gabelli Utility Trust operates as a diversified closed-end investment management company. The fund's primary objective is the long-term growth of capital and income. To achieve its objective, the fund may invest its assets in common stocks and other securities of foreign and domestic companies involved in providing products, services, or equipment for the generation or distribution of electricity, gas, & water; and telecommunications services or infrastructure operations. It invests in various sectors, of which Electric Integrated, Water, Telecommunications, and U.S. Government Obligations and others.
About TNGX Tango Therapeutics Inc.
Tango Therapeutics Inc is a biotechnology company. It is dedicated towards discovering novel drug targets and delivering the next generation of precision medicine for the treatment of cancer. It is engaged in the business of discovering and developing precision oncology therapies. Its program TNG908, is an MTA-cooperative inhibitor of PRMT5 designed to work selectively in cancer cells with an MTAP deletion. Its pipeline further consists of discovery programs such as, TNG462, TNG348, TNG260 and others for multiple cancer types with limited treatment options.